Last reviewed · How we verify

oral ciprofloxacin plus inhaled colistin

Universitaire Ziekenhuizen KU Leuven · FDA-approved active Small molecule

oral ciprofloxacin plus inhaled colistin is a Antibiotic combination (fluoroquinolone + polymyxin) Small molecule drug developed by Universitaire Ziekenhuizen KU Leuven. It is currently FDA-approved for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection. Also known as: Ciproxin ® - ciprofloxacin, Colistineb ®.

Ciprofloxacin and colistin are combined to provide synergistic bacterial killing through different mechanisms: ciprofloxacin inhibits DNA gyrase while colistin disrupts bacterial cell membranes.

Ciprofloxacin and colistin are combined to provide synergistic bacterial killing through different mechanisms: ciprofloxacin inhibits DNA gyrase while colistin disrupts bacterial cell membranes. Used for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection.

At a glance

Generic nameoral ciprofloxacin plus inhaled colistin
Also known asCiproxin ® - ciprofloxacin, Colistineb ®
SponsorUniversitaire Ziekenhuizen KU Leuven
Drug classAntibiotic combination (fluoroquinolone + polymyxin)
TargetDNA gyrase (ciprofloxacin); bacterial cell membrane (colistin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Respiratory
PhaseFDA-approved

Mechanism of action

Oral ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Inhaled colistin is a polymyxin antibiotic that binds to and disrupts the outer membrane of gram-negative bacteria. The combination targets multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa in cystic fibrosis, through complementary mechanisms to enhance bacterial eradication.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oral ciprofloxacin plus inhaled colistin

What is oral ciprofloxacin plus inhaled colistin?

oral ciprofloxacin plus inhaled colistin is a Antibiotic combination (fluoroquinolone + polymyxin) drug developed by Universitaire Ziekenhuizen KU Leuven, indicated for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection.

How does oral ciprofloxacin plus inhaled colistin work?

Ciprofloxacin and colistin are combined to provide synergistic bacterial killing through different mechanisms: ciprofloxacin inhibits DNA gyrase while colistin disrupts bacterial cell membranes.

What is oral ciprofloxacin plus inhaled colistin used for?

oral ciprofloxacin plus inhaled colistin is indicated for Cystic fibrosis with chronic Pseudomonas aeruginosa lung infection.

Who makes oral ciprofloxacin plus inhaled colistin?

oral ciprofloxacin plus inhaled colistin is developed and marketed by Universitaire Ziekenhuizen KU Leuven (see full Universitaire Ziekenhuizen KU Leuven pipeline at /company/universitaire-ziekenhuizen-ku-leuven).

Is oral ciprofloxacin plus inhaled colistin also known as anything else?

oral ciprofloxacin plus inhaled colistin is also known as Ciproxin ® - ciprofloxacin, Colistineb ®.

What drug class is oral ciprofloxacin plus inhaled colistin in?

oral ciprofloxacin plus inhaled colistin belongs to the Antibiotic combination (fluoroquinolone + polymyxin) class. See all Antibiotic combination (fluoroquinolone + polymyxin) drugs at /class/antibiotic-combination-fluoroquinolone-polymyxin.

What development phase is oral ciprofloxacin plus inhaled colistin in?

oral ciprofloxacin plus inhaled colistin is FDA-approved (marketed).

What are the side effects of oral ciprofloxacin plus inhaled colistin?

Common side effects of oral ciprofloxacin plus inhaled colistin include Nausea, Diarrhea, Abdominal pain, Tendinopathy (ciprofloxacin), Nephrotoxicity (colistin), Neurotoxicity (colistin).

What does oral ciprofloxacin plus inhaled colistin target?

oral ciprofloxacin plus inhaled colistin targets DNA gyrase (ciprofloxacin); bacterial cell membrane (colistin) and is a Antibiotic combination (fluoroquinolone + polymyxin).

Related